Kintor Pharmaceutical (HKSE:09939) Inventories, Work In Process: HK$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09939 Kintor Pharmaceutical Ltd HKSE:09939
25 GF Score
Price HK$1.64
! 3 Warning Signs
View Full Analysis

What is Kintor Pharmaceutical Inventories, Work In Process?

Kintor Pharmaceutical HKSE:09939 -1.20% 25 Inventories, Work In Process is HK$0.00 Mil as of Dec. 2025. GuruFocus rates HKSE:09939 with a GF Score™ of 25/100. The stock has 3 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Kintor Pharmaceutical's work in process for the quarter that ended in Dec. 2025 was HK$0.00 Mil.

Kintor Pharmaceutical Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Kintor Pharmaceutical's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kintor Pharmaceutical Inventories, Work In Process Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial 6.22 0.00 0.00 0.00 0.00

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:09939
25GF Score
Kintor Pharmaceutical Ltd HKSE:09939
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kintor Pharmaceutical Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of HK$0.00 Mil mean?
Kintor Pharmaceutical (HKSE:09939) has a Inventories, Work In Process of HK$0.00 Mil as of Dec. 2025. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Kintor Pharmaceutical and its competitors.
Is Kintor Pharmaceutical's Inventories, Work In Process too high?
Kintor Pharmaceutical's current Inventories, Work In Process is HK$0.00 Mil. Overall, Kintor Pharmaceutical has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's Inventories, Work In Process compare to VRTX and REGN?
Kintor Pharmaceutical's Inventories, Work In Process of HK$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Kintor Pharmaceutical and its competitors. Kintor Pharmaceutical's current Inventories, Work In Process is HK$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (HKSE:09939) has a current Inventories, Work In Process of HK$0.00 Mil. The current Inventories, Work In Process is HK$0.00 Mil. Kintor Pharmaceutical's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Kintor Pharmaceutical (HKSE:09939), the current Inventories, Work In Process is HK$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kintor Pharmaceutical Business Description

Other Exchanges KNTPF:USA
Address No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
25GF Score

Get the complete analysis for HKSE:09939

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.64
Price